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Development and Large Scale Manufacturing of 
Exosome-Based Therapeutics
Konstantin Konstantinov, Ph.D.
SVP, Manufacturing & Process Sciences
Integrated Continuous Biomanufacturing III Conference
Hotel Cascais Miragem, Cascais, Portugal, Sep 17-21, 2017 
2Cascais Rio
Beautiful Cascais
32002:  B&B – USP/DSP integration using 
annular chrom (Bayer)
1996:  B&B – large scale continuous 
NS0 process for Mab (Bayer)
1989:  B&B - SCP continuous process 
optimization & control (Osaka U)
1970s:  SCP continuous process 
using methanol (ICI)
2004:  ACS industrial award to Bayer 
for perfusion technology dev
Brief history of my involvement with continuous 
bioprocessing
2012: B&B – Integrated continuous 
biomanufacturing (Genzyme)
2014: Progress with continuous Mab 
production (Genzyme)
2015: Capacity of a fully integrated 
continuous system (Genzyme)
4W. Ross Ashby (1956): An Introduction to Cybernetics
The principle of requisite variety
If a system is to be stable, the number of states of its control mechanism must be 
greater than or equal to the number of states in the system being controlled.
“ …. only variety can destroy variety "
An Expert Approach for Control of Fermentation Processes as Variable Structure Plants.  J. Ferment. Bioeng., 70, 48-57 (1990)
Exosomes:  A new modality with a tremendous therapeutic potential
5Biotherapeutic Modalities and Technologies for Their Manufacturing:  
Importance of Multi-Modality Production Platforms
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Preferred approach:
Multi-modality tech platforms
Continuous bioprocessing 
belongs here 
6Exosome Science and Bioprocess Engineering 
have evolved independently
Bioprocess Engineering
• Rich experience with MAbs & rProteins
• Upstream/Downstream/Fill-finish
• Cell Culture Engineering
• Protein Recovery
• Analytics & Characterization
• Mature, yet fast advancing
• Industry dominated
Exosome Science
• New field
• Rapidly advancing, but not yet mature
• Driven by academia (2016 ISEV:  95% 
academic participants)
• Few companies, mostly startups
• No large scale applications
• Tremendous therapeutic potential
Codiak
• Bridge the two fields
• Integrate the best science & 
process technology  
• Hire people from both fields
7Exosomes: A New Biotherapeutic Modality
Introduction to Exosome Biology
Approach to Exosome Manufacturing
Recent Results and Path Forward
Biological
Research
CMC
Knowledge
8
Nikki Ross, Codiak BioSciences exosome isolation data
Exosomes:  Next Generation Biologicals
EM image: Purified exosomes from human cells
9Exosome Biology
Subclass of Extracellular Vesicles
Produced by all living cells
Native information carrier between tissues
Protected from the immune system
10
Mechanisms for Exosome Uptake by Cells
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Exosome Terminology Can Be Confusing
• Many “-somes” in the literature
- Exosomes, endosomes, ectosomes, oncosomes, dectosomes, connectosomes, 
gohstosomes, vexosomes, FedExosomes, …
• No standard definition translatable into characterization methods
• Typical exosome attributes
- Size (40~200 nm)
- Canonical surface proteins (CD9, CD47, CD63, CD81, etc.)
- Relevant functional assays (uptake, biodistribution, etc.)
- However, above attributes overlap with other Extracellular Vesicles
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Explosion in Exosome Knowledge
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2007  Citations: >4500
Professor Jan Lotvall,
Chief Scientist, Codiak
13
Rapidly Growing Number of Exosome Companies
Exosomes: A New Biotherapeutic Modality
Introduction to Exosome Biology
Approach to Exosome Manufacturing
Biological
Research
CMC
Knowledge
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Recent Results and Path Forward
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Challenges in Exosome Manufacturing
• New scientific field, so far driven mostly by academia.  
Low level of maturity and standardization
• Limited analytics & characterization
• Insufficient sample purity complicating data interpretation
• High complexity
• Non-scalable exosome production process
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Nanoparticle Tracking Analysis (NTA) is used routinely for exosome 
titer & size characterization
However, NTA does not differentiate exosomes from non-exosome particles 
F1:
Mean 162.5nm
Mode 112.1nm
2.6x1011 P/ml 
F2:
Mean 149.1nm
Mode 122.2nm
3.0x1011 P/ml 
F3:
Mean 173.3nm
Mode 109.4nm
3.0x1011 P/ml 
F4:
Mean 159.1nm
Mode 154.9nm
1.2x1011 P/ml 
F1
F2
F3
F4
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A Typical Current (Academic) Process
Grow adherent cells (typically primary MSCs) in serum
Wash and remove old media, grow cells without serum
2000 g spin, 30 minutes, 4C to remove cells (discard pellet)
12000 g spin, 45 minutes, 4C to remove cell debris (discard pellet)
Dilute supernatant in sucrose cushion
110,000 g spin, 120 minutes, 4C (discard supernatant)
Resuspend pellet and wash in PBS
110,000 g spin, 70 minutes, 4C (discard supernatant)
Perform particle count, freeze in PBS or alternate solutionResuspend pellet and wash in PBS
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Nucleic Acids – DNA, RNA
Small Molecules
Antibody
CRISPR
Lipids
The Codiak Exosome Platform
SURFACE ENGINEERING LOADING SPECIFIC PAYLOADS
LOCAL OR SYSTEMIC DELIVERY COMBINATORIAL POTENTIAL
Agonist
Uptake
Immune 
Tolerance
Antagonist
Tropism
CD47
mAb
receptor
ligand
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Plug-and-Play Manufacturing Technology:
Integration of Codiak’s Biological and Production Platforms
Static Component (Production Process)
Bioreactor Purification Loading Formulation
Three Variable Components (Cell Lines, Payloads, Delivery Routes)
Advanced Upstream, Downstream, Analytics | Scalable | Low COGS
Engineered 
Cell Lines/Exosomes
Payloads
Delivery 
routes
Exosomes: A New Biotherapeutic Modality
Introduction to Exosome Biology
Approach to Exosome Manufacturing
Biological
Research
CMC
Knowledge
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Recent Results and Path Forward
21
Targeting KRAS with siRNA-Loaded Exosomes
PBS Control Exo siKras G12D iExo
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Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar, Valerie S. LeBleu, Hikaru Sugimoto, Sujuan Yang, Carolina F. Ruivo, Sonia A., Melo, J. Jack Lee & Raghu Kalluri
Nature (2017)    doi:10.1038/nature22341, Received 20 September 2016   Accepted 03 April 2017   Published online  07 June 2017
Intra-venous Intra-peritoneal
Distribution of Exosomes in Healthy Tissues
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fundamentals
Steady growth
Introduction of Advanced New Technologies
Internet, monoclonal antibody, electric cars, gene therapy, etc. 
Where is exosome technology and Codiak?
Internet
MoAb
Electric cars
Gene therapy
Exosomes
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ICB
Moving forward …
Continuous 
biomanufacturing
Exosomes+
Stay tuned!
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To the awesome ICB community -
academia & industry:  Thank you !
ICB 3 organizers
• Chetan Goudar
• Suzy Farid
• Paula Alves
• Veena Warikoo
ECI & ICB colleagues & friends
• Manuel Carrondo
• Wei-Show Hu
• Jamie Piret
• Mike Betenbaugh
• Barry Buckland
• Barbara Hickernell
• Tressa D’Ottavio
My Bayer days
• Dr. Hans Henzler
• Chetan Goudar
• Jim Michaels
• Chun Zhang
• John Thrift
• John Murphy
• David Naveh
My Genzyme days
• Veena Warikoo
• Rahul Godawat
• Chris Hwang
• Claudia Buser
• Weichang Zhou
• Jason Walther
• Jin Yin
• Marcella Yu
• Jean McLarty
Codiak
• Scott Estes
• Kathryn Golden
• Agata Villager
• Damian Houde
• Mike Mercaldi
and many, many others …
Academia:  Prof. Cooney (MIT),  Prof. Yoshida (Osaka U)
